Neoadjuvant chemoimmunotherapy may beat immunotherapy alone when it comes to pathologic response, but its impact on survival remains to be seen.
Buparlisib plus paclitaxel did not improve overall survival compared to paclitaxel alone in PD-1/PD-L1-pretreated recurrent/metastatic HNSCC patients. The combination showed a higher overall response ...
The OriGAMI-4 trial reveals subcutaneous Rybrevant's 45% response rate in metastatic head and neck cancer patients after immunotherapy and platinum.
A new report has laid bare how head and neck cancers have "persistently poor" survival rates in our region.
Ten percent higher 5-year overall survival rates in patients receiving precise proton therapy vs. traditional radiation therapy Patients had significantly fewer side effects and improved quality of ...
LOUISVILLE, Ky. (WDRB) -- According to the American Cancer Society, people with cancer are living longer than ever before. The organization credited large advancements in cancer research. "This is one ...
Less-invasive robotic surgery for upper airway and digestive track malignant tumors is as effective as other minimally invasive surgical techniques based on patient function and survival, according to ...
All seven northern Integrated Care Boards have higher rates of head and neck cancer than the England average. Six also have higher death rates, with the North East and North Cumbria the worst in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results